Dr. Reddy’s Laboratories has disclosed that its Bachupally, Hyderabad-based biologics manufacturing unit received five observations from the US Food and Drug Administration (FDA) following a recent inspection. The company stated it will respond to the regulator within the stipulated timeframe.
According to The Economic Times, the inspection was conducted between September 4 and 12 as part of a Pre-Approval Inspection (PAI). The FDA issued a Form 483, which outlines areas where conditions may potentially be in violation of the Food, Drug, and Cosmetic Act or associated regulations. While Dr. Reddy’s did not specify the nature of the observations, it emphasized its intent to address them promptly.
Form 483 observations are not enforcement actions but serve as early warnings, providing companies the opportunity to correct deficiencies before the FDA considers further measures. For Indian drugmakers, timely remediation is critical, given the US remains a key export market and accounts for a significant share of revenues.
The development underscores ongoing regulatory scrutiny of Indian pharmaceutical facilities, particularly in biologics, a fast-growing segment where compliance standards are stringent. Successful closure of the observations will be important for Dr. Reddy’s pipeline progress and global supply commitments.
